DPP4 and type 2 diabetes mellitus: In a cohort study on 90,880 patients with type 2 diabetes previously treated with metformin as a first-line antihyperglycemic drug, the add-on of DPP-4 inhibitors (mostly sitagliptin) as a second-line therapy was found to be associated with a lower risk of AF development than the use of other drugs (mainly SUs) as the second antidiabetic medication [38].